On 21 July 2022 the CMA imposed fines of £63m on Pfizer and £6.7m on Flynn in relation to the excessive pricing of the generic drug phenytoin, an anti-epilepsy drug. This comes nearly six years on from the CMA’s first infringement decision in relation to the conduct. That first decision imposed fines of £84.2m on … Continue reading Phenytoin – was it worth it? →